Approval Year
Name | Type | Language |
---|
Showing 1 to 5 of 8 entries
Classification Tree | Code System | Code |
---|
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG | 633218 | ||
|
EU-Orphan Drug | EU/3/21/2555 | ||
|
EU-Orphan Drug | EU/3/18/1992 | ||
|
FDA ORPHAN DRUG | 825421 | ||
|
FDA ORPHAN DRUG | 527316 |
Showing 1 to 5 of 5 entries
Code System | Code | Type | Description |
---|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Efgartigimod alfa | PRIMARY | |||
|
961YV2O515 | PRIMARY | |||
|
C171817 | PRIMARY | |||
|
2587717 | PRIMARY | |||
|
961YV2O515 | PRIMARY |
Showing 1 to 5 of 9 entries
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Related Record | Type | Details |
---|
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TARGET -> INHIBITOR |
An antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood.[2] The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis.
|
Showing 1 to 3 of 3 entries
Related Record | Type | Details |
---|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Showing 1 to 1 of 1 entries
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
ESTIMATED
C2310H3564O688N604S14 |
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
ESTIMATED
51300 Da (average) |
Showing 1 to 2 of 2 entries